Olema Pharmaceuticals, Inc. (OLMA): R&D Expense
$157.70M
Year ended 2025-12-31
$190.19M
Trailing 12 months to 2026-06-30
+24.2%
3-year compound annual growth
+63.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $157.70M | +26.6% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $124.52M | +44.6% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $86.14M | +4.7% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $82.27M | +61.0% | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | $51.10M | +272.9% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $13.70M | +249.6% | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | $3.92M | n/a | 2022-02-28, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $157.70M | +26.6% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $145.64M | +75.2% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $258.78M | +7.1% |
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | $151.39M | +19.2% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $33.30M | +42.4% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $94.79M | +55.6% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $71.53M | +36.7% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $25.99M | -9.9% |
| Geron Corp (GERN) | 2025-12-31 | $71.43M | -31.1% |
Compare OLMA, DNTH, SNDX, EWTX side by side · Screen every company in Pharmaceutical Preparations ↗